IL152571A - Process for the preparation of high purity pemirolast - Google Patents

Process for the preparation of high purity pemirolast

Info

Publication number
IL152571A
IL152571A IL152571A IL15257102A IL152571A IL 152571 A IL152571 A IL 152571A IL 152571 A IL152571 A IL 152571A IL 15257102 A IL15257102 A IL 15257102A IL 152571 A IL152571 A IL 152571A
Authority
IL
Israel
Prior art keywords
pemirolast
preparation
high purity
amines
carried out
Prior art date
Application number
IL152571A
Other versions
IL152571A0 (en
Original Assignee
Dinamite Dipharma S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dinamite Dipharma S P A filed Critical Dinamite Dipharma S P A
Priority to IL152571A priority Critical patent/IL152571A/en
Publication of IL152571A0 publication Critical patent/IL152571A0/en
Publication of IL152571A publication Critical patent/IL152571A/en

Links

Description

ίΐίΐι_ι> w»i w t ot? ^i tta nianb A process for the preparation of high purity pemirolast DINAMITE DIPHARMA S.p.A. abbreviated DIPHARMA S.p.A C. 141532 A PROCESS FOR THE PREPARATION OF HIGH PURITY PEMIROLAST The present invention relates to a novel process for the purification of Pemirolast, whose potassium salt is an anti-allergic pharmaceutical product.
Pemirolast, or 9-methyl-3-(lH-tetrazol-5-yl)-4H-pyrido-[l ,2-a]-pyrimidin-4-one, has the following formula: Several patents disclose processes for the preparation of Pemirolast Potassium.
According to all known methods, the product is firstly obtained in the acid form and then converted into the corresponding potassium salt.
As the product recovered in the acid form is very poorly soluble in conventional solvents, it always contains several by-products which can hardly be removed and only with remarkable losses in yields. The purification is usually carried out either directly on the acid form or on the corresponding potassium salt.
A novel process for the purification of Pemirolast acid form which provides high purity (>99,8% HPLC) and high yields (>85%) has now been found, and this is the object of the present invention.
The process of the invention comprises the salification of Pemirolast acid form in the presence of an amount of a primary or secondary amine ranging from 1 equivalent to 1.5 equivalents relative to Pemirolast and an amount of protic solvents such as water, Cj-Cs-alcohols or mixtures thereof ranging from 1 volume to 10 volumes relative to Pemirolast. The use of a 2 : 1 methanol : water mixture is preferred.
The salification is carried out at a temperature which allows to completely solubilize the salt, generally at a temperature ranging from 20 to 100°C, preferably from 40 to 80°C. When the solubilization is complete, the solution is acidified with mineral or organic acids to pH ranging from 2 to 4 in order to promote the precipitation of Pemirolast in the acid form which is then filtered, washed and dried to give a product with >99.8% HPLC purity. Suitable acids comprise formic acid, acetic acid and hydrochloric acid.
Said product can then be transformed into the corresponding potassium salt without further purification.
Primary amines for use according to the invention are CrC6-alkylamines, or arylamines wherein the aryl residue can be phenyl, naphthyl or an optionally substituted aromatic heterocyclic nucleus.
Secondary amines for use according to the invention are di(Ci- C6)alkylamines, alkylarylamines or diarylamines, wherein the alkyl or aryl residues are as defined above, or are an aliphatic and aromatic substituent and wherein the meanings for aliphatic and aromatic are those indicated above.
The invention is illustrated in greater detail in the following examples. Example 1 A suspension of 9-methyl-3-(lH-tetrazol-5-yl)-4H-pyrido-[l,2-a]-pyrimidin-4-one (68.5 g; 0.3 mols) in methanol (420 ml) and water (210 ml) heated at 50°C is added with a 40% N-methylamine aqueous solution (30 ml, 0.35 mols) to pH = 10. The solution is heated at 68-70°C, and acidified with formic acid (21 ml) to pH = 3. After completion of the addition the mixture is kept at 68-70°C for about 15 minutes and then cooled to 20-25°C. The precipitate is filtered, washed with methanol and dried under vacuum at 40°C to give 9-methyl-3-(lH-tetrazol-5-yl)-4H-pyrido-[l ,2-a]-pyrimidin-4-one with >99.8% HPLC purity (63 g, 92% yield).
Example 2 9-Methyl-3-(lH-tetrazol-5-yl)-4H-pyrido-[l,2-a]-pyrimidin-4-on^ (63 g, 0.28 mols) is suspended in methanol (1000 ml). The resulting suspension is kept at 45°C and slowly added with a 45% potassium hydroxide aqueous solution to pH 9-9.5. The suspension is stirred at 45°C for about 15 minutes and then cooled to 20°C. The precipitate is filtered, washed with methanol and dried under vacuum at 80°C, to obtain Pemirolast Potassium (71.9 g; 0.27 mols, 96% yield) with HPLC purity >99.8%. lH NMR(D20, TMS) d (ppm): 2.02 (s, 3H); 6.83 (t, 1H); 7.27 (d, lH); 8.18 (s, 1H); 8.47 (d, lH).

Claims (5)

1. A process for the purification of Pemirolast comprising: a) salifying crude Pemirolast with a primary or secondary amine in the presence of solvents selected from water, CrC3 alcohols or mixtures thereof; b) acidifying the solution obtained in a) by addition of mineral or organic acids to pH ranging from 2 to 4; c) isolating precipitated Pemirolast and optionally transforming it — ' into the corresponding potassium salt.
2. A process as claimed in claim 1 wherein primary amines are selected from CrC6 aliphatic amines or arylamines.
3. A process as claimed in claim 1 wherein secondary amines are selected from di(C1-C6)alkylamines, alkylarylamines or diarylamines.
4. A process as claimed in any one of claims 1 to 3 wherein step a) is carried out in a 2 : 1 methanol/water mixture.
5. A process as claimed in any one of claims 1 to 4, wherein step b) is carried out with formic acid.
IL152571A 2002-10-31 2002-10-31 Process for the preparation of high purity pemirolast IL152571A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL152571A IL152571A (en) 2002-10-31 2002-10-31 Process for the preparation of high purity pemirolast

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL152571A IL152571A (en) 2002-10-31 2002-10-31 Process for the preparation of high purity pemirolast

Publications (2)

Publication Number Publication Date
IL152571A0 IL152571A0 (en) 2003-05-29
IL152571A true IL152571A (en) 2008-04-13

Family

ID=29765101

Family Applications (1)

Application Number Title Priority Date Filing Date
IL152571A IL152571A (en) 2002-10-31 2002-10-31 Process for the preparation of high purity pemirolast

Country Status (1)

Country Link
IL (1) IL152571A (en)

Also Published As

Publication number Publication date
IL152571A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
EP1285921B1 (en) A process for the preparation of high purity pemirolast
US8912325B2 (en) Process for preparation of imatinib and its mesylate salt
NZ563636A (en) Preparation of famciclovir and other purine derivatives
PL192461B1 (en) Method of obtaining 8-methoxy-quinolinocarboxylic acids
CA2373077A1 (en) Salts of 2,2-dimethyl-1,3-dioxane intermediates and process for the preparation thereof
CA2368815A1 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
US8680319B2 (en) Method for producing antifolate agents having glutamic acid part in their structure
US20100197910A1 (en) Process for preparation of prulifloxacin using novel intermediates
JP4208463B2 (en) Intermediates for the production of quinolonecarboxylic acid derivatives
KR100724311B1 (en) Process for Production of Naphthyridine-3-Carboxylic Acid Derivatives
EP1857458A1 (en) Process for the preparation of abacavir
IL152571A (en) Process for the preparation of high purity pemirolast
US6576764B2 (en) Synthesis and crystallization of piperazine ring-containing compounds
EP2547663A1 (en) A process for the preparation of highly pure ambrisentan
NZ554731A (en) Novel Intermediates Useful For The Preparation Of Aripiprazole And Methods For The Preparation Of The Novel Intermediates And Aripiprazole
EP0052959B1 (en) Production of purine derivatives and intermediates therefor
KR0157422B1 (en) Process for production of 6-(3-dimethylamino-propionyl)forskolin
US20120259116A1 (en) Novel Process for the Preparation of Paliperidone
US20030135043A1 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
CA1326239C (en) Preparation of ciprofloxacin
JP2001278865A (en) Method for producing 4-aminoquinolines

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees